
PSK Pharma (part of the Rus Biopharm group of companies) is an integrated biopharmaceutical company that produces medicines in the Dubna SEZ (special economic zone) for the treatment of socially significant diseases in various nosologies in a full cycle, including the synthesis of substances. Priority areas of activity: genetically engineered biological drugs, a full line of drugs for the treatment of asthma and COPD, drugs for targeted therapy of autoimmune and orphan diseases. The plant develops and manufactures drugs for the treatment of HIV, tuberculosis, diseases of the gastrointestinal tract and central nervous system.

The Long Sheng Pharma group of companies has been operating in the pharmaceutical market since 1995. The main office of the company is located in Hong Kong and has represented the interests of the ARPM in the People's Republic of China since 2015, and in Hong Kong since 2016. In the Russian market, the key activity of the company at first was the supply of pharmaceutical substances and excipients for the production of finished dosage forms. Today the company offers its customers complex industrial solutions, while continuing to expand its product portfolio.

An international pharmaceutical company represented by production sites and research and development centers around the world. The company manufactures affordable, high-quality medicines that are trusted by healthcare professionals and patients in more than 150 countries around the world. In Russia, the company is represented by a commercial and production division.